Experiment: 6DO6

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	1 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 20 mM sodium phosphate, 50 mM sodium chloride, pH 5.5 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	298	Bruker AVANCE III 600
2	2D 1H-13C HSQC aliphatic	1 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 20 mM sodium phosphate, 50 mM sodium chloride, pH 5.5 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	298	Bruker AVANCE III 600
3	2D 1H-13C HSQC aromatic	1 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 20 mM sodium phosphate, 50 mM sodium chloride, pH 5.5 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	298	Bruker AVANCE III 600
4	3D HNCA	1 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 20 mM sodium phosphate, 50 mM sodium chloride, pH 5.5 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	298	Bruker AVANCE III 600
5	3D HNCACB	1 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 20 mM sodium phosphate, 50 mM sodium chloride, pH 5.5 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	298	Bruker AVANCE III 600
6	3D CBCA(CO)NH	1 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 20 mM sodium phosphate, 50 mM sodium chloride, pH 5.5 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	298	Bruker AVANCE III 600
8	3D 15N-edited [1H,1H]-NOESY	1 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 20 mM sodium phosphate, 50 mM sodium chloride, pH 5.5 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	298	Bruker AVANCE III 800
7	3D 13Cali-edited [1H,1H]-NOESY	1 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 20 mM sodium phosphate, 50 mM sodium chloride, pH 5.5 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	298	Bruker AVANCE III 800
9	3D 13Caro-edited [1H,1H]-NOESY	1 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 20 mM sodium phosphate, 50 mM sodium chloride, pH 5.5 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	298	Bruker AVANCE III 800

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE III	600
2	Bruker	AVANCE III	800

NMR Refinement
Method	Details	Software
molecular dynamics	the structures are based on a total of 3098 NOE-derived restraints, 208 dihedral angle restraints, 60 distance restraints from hydrogen bonds	CYANA
Constrained energy minimization		OPALp

NMR Ensemble Information
Conformer Selection Criteria	structures with acceptable covalent geometry
Conformers Calculated Total Number	40
Conformers Submitted Total Number	10
Representative Model	1 (closest to the average)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	collection	TopSpin		Bruker Biospin
2	processing	TopSpin		Bruker Biospin
3	chemical shift assignment	CARA		Keller and Wuthrich
4	peak picking	CARA		Keller and Wuthrich
5	refinement	CYANA		Guntert, Mumenthaler and Wuthrich
6	structure calculation	UNIO10-ATNOS/CANID	2.0.2	Dr. Torsten Herrmann
7	refinement	OPALp		Koradi et al, 2000
8	refinement	Prime		Prime, Schrodinger, LLC, New York, NY, 2018
9	structure calculation	CYANA		Guntert, Mumenthaler and Wuthrich

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.